QURE UNIQURE NV

uniQure to Participate in Multiple Upcoming Investor Conferences in April

uniQure to Participate in Multiple Upcoming Investor Conferences in April

LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming investor events in April:

  • Stifel CNS Day Virtual Conference, Wednesday April 1, 2020.



    • David Cooper, M.D., vice president of clinical research CNS, will participate in the panel discussion, “A Deep Dive into Disease Modifying Strategies in Huntington’s Disease”, on Wednesday April 1st at 10:00 a.m. EDT. 



    • , chief executive officer at uniQure, will participate in the panel discussion, “The Promise and Challenges Associated with Gene Therapy in CNS” on Wednesday April 1st at 10:45 a.m. EDT.

     
  • SunTrust Corporate Access Call Series: After the Dust Settles, Friday April 3, 2020. 



    • Matt Kapusta, chief executive officer, and , senior vice president investor relations and corporate communications, will participate in SunTrust’s conference call series, “After the Dust Settles” on Friday April 3rd, at 11:00 a.m. EDT.

     
  • 2020 Virtual Biotech Corporate Access Day hosted by Wells Fargo, April 7&9, 2020.



    • Members of uniQure’s management team will be available for virtual investor meetings throughout the day on Tuesday, April 7th.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts:

 
FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorEva M. Mulder Tom Malone
Direct: 339-970-7536Direct: Direct:  339-970-7558
EN
30/03/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces $200 Million Proposed Public Offering

uniQure Announces $200 Million Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters ...

12h / 58m 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Refinancing of Existing $50 Million Debt and Securin...

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding ~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ approval ~ ~ Transaction provides financial flexibility and improves cost of capital ~ LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing trans...

21h / 55m 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Positive Topline Results from Pivotal Phase I/II Stu...

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 m...

22h 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained I...

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease ~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 has a manageable safety profile at the highest dose ~ ~ Updated clinical results expected in the first half of 2026 ~ LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading ge...

September 5, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Second Quarter 2025 Financial Results and Highlights...

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow u...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch